Sitewide Sale! 15% OFF Use Code EPX15 *
Gentacalm Topical Spray - Dechra is used for the treatment of infected superficial skin lesions in dogs caused by bacteria sensitive to gentamicin. Gentacalm Spray provides antibacterial and anti-inflammatory activity to irritated and infected skin lesions.
A quick application of Gentacalm Topical Spray to your dog's skin relieves itching, painful, swollen spots caused by bacterial skin infections. Gentacalm contains the active ingredient, gentamicin, a broad-spectrum antibiotic that's highly effective against a range of bacterial skin infections. This fast-acting spray also contains betamethasone valerate, which stops itching, and swelling at the site of the infection. Gentacalm is odorless and colorless so it won't stain or leave residue on your dog's fur on surfaces in your home. The convenient spray formula offers a no-mess, direct way to apply the medication to the infected area.
Gentacalm contains gentamicin as its active ingredient, which is a highly potent broad spectrum antibiotic that fights a variety of bacterial skin infections. The quick-acting spray also contains betamethasone valerate, known to stop swelling and itching at the infection site.
For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.
View GentaCalm Spray Drug Facts Sheet.
Prior to treatment, remove exces-sive hair and clean the lesion and adjacent area. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2 to 4 times daily for 7 days.
Each depression of the sprayer head delivers 0.7 mL of Gentamicin Sul-fate With Betamethasone Valerate Topical Spray.
Gentamicin sulfate with betamethasone valerate topical spray was well-tolerated in an abraded skin study in dogs. No treatment-related toxicological changes in the skin were observed.
Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs.Vomiting and diarrhea (occasionally bloody) have been observed in dogs.
Cushing's syndrome in dogs has been reported in association with pro-longed or repeated steroid therapy.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to use of this preparation. Use of topical antibi-otics may permit overgrowth of non-susceptible bacteria, fungi oryeasts. If this occurs, treatment should be instituted with other appropriate agents as indicated.
Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.
Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal.
In patients presently receiving or recently withdrawn from systemic cortico-steroids treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.
If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage, which includes sodium retention, potassium loss, fluid retention, weight gains, polydipsia and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.
Clinical and experimental data have demonstrated that cortico-steroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of preg-nancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.
Additionally, corticosteroids administered to dogs, rabbits and rodents dur-ing pregnancy have produced cleft palate. Other congenital anomalies, in-cluding deformed forelegs, phocomelia and anasarca, have been reported in offspring of dogs which received corticosteroids during pregnancy.
If hypersensitivity of any of the components oc-curs, discontinue treatment and institute appropriate therapy.
Store upright between 2°C and 30°C (36°F and 86°F).
Features of Gentacalm:
Potential adverse reactions following systemic or parenteral synthetic corticosteroid use include:
Repeated or prolonged steroid treatment has been associated with Cushing's syndrome.